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Matrix metalloproteinases4F2hc is a type-II glycoproteinwhose covalent-bound association with one of several described light chains yields
a heterodimer mainly involved in large neutral amino acid transport. Likewise, it is well known that the heavy
chain interacts with β-integrins mediating integrin-dependent events such as survival, proliferation, migration
and even transformation. 4F2hc is a ubiquitous protein whose overexpression has been related to tumor develop-
ment and progression. Stable silencing of 4F2hc inHeLa cells using an artiﬁcialmiRNA impairs in vivo tumorigenic-
ity and leads to an ineffective proliferation response to mitogens. 4F2hc colocalizes with β1-integrins and CD147,
but this interaction does not occur in lipid rafts in HeLa cells. Moreover, silenced cells present defects in integrin-
(FAK, Akt and ERK1/2) and hypoxia-dependent signaling, and reduced expression/activity of MMP-2. These alter-
ations seem to be dependent on the inappropriate formation of CD147/4F2hc/β1-integrin heterocomplexes on the
cell surface, arising when CD147 cannot interact with 4F2hc. Although extracellular galectin-3 accumulates due to
the decrease inMMP-2 activity, galectin-3 signaling events are blocked due to an impaired interactionwith 4F2hc,
inducing an increased degradation of β-catenin. Furthermore, cell motility is compromised after protein silencing,
suggesting that 4F2hc is related to tumor invasion by facilitating cellmotility. Therefore, herewe propose a molec-
ular mechanism by which 4F2hc participates in tumor progression, favoring ﬁrst steps of epithelial–mesen-
chymal transition by inhibition of β-catenin proteasomal degradation through Akt/GSK-3β signaling and
enabling cell motility.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
4F2hc (also known as CD98hc or SLC3A2) was ﬁrst described as part
of a cell-surface antigen which led to T-lymphocyte activation [1]; since
then, several additional cell functions have been described. This type-II
glycoprotein is covalently bound to one of several described light chains,
allowing them to reach the membrane and then enabling heteromeric
amino acid transport that eventually regulates mTOR pathway [2,3]. In
addition, 4F2hc is involved in many other different cell functions, from
thyroid hormone transport and energetic metabolism, to modulation of
integrin-dependent processes. This multiple functionality is in accor-
dance with its ubiquitous expression (with exception of platelets).erald green ﬂuorescent protein;
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rights reserved.4F2hc associates with β-integrins (mainly β1 but also β3) through
their cytoplasmic and transmembrane domains, mediating integrin-
dependent events such as survival, proliferation, migration and evenma-
lignant transformation [4–6]. Its deletion in embryonic stem cells impairs
integrin-dependent signaling pathways such as FAK (Focal Adhesion
Kinase), Rac and Akt, increases anchorage-independent induced apopto-
sis (anoikis) andmarkedly reduces in vivo teratocarcinoma formation [5].
Furthermore, 4F2hc is highly expressed in tumors of different origins as
well as in established tumor cell lines, and it has been suggested that its
overexpression mediates malignant transformation via its interaction
with β1-integrins [7]. This overexpression also promotes cell survival
and proliferation [8,9], whereas 4F2hc deletion induces cell death via
apoptosis [8,10]. Moreover, 4F2hc could even be implicated in the acqui-
sition of a multidrug resistant phenotype [11]. Therefore, 4F2hc has been
proposed as a potential tumor marker as its overexpression is an indica-
tor of poor prognosis in patients who have suffered breast, lung and
several other types of cancer, and is currently under study as a prospec-
tive therapeutic target [12–15].
On the other hand, 4F2hc has been reported to be part of a
multicomponent complex in the cell membrane which includes CD147,
EpCAM and the amino acid transporter ASCT2 [16]. CD147, also known
as EMMPRIN (Extracellular Matrix MetalloPRoteinase INducer), acts as
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and leads them towards the cell membrane where they carry out
transport of lactate and pyruvate [17]; it also interacts with β1-integrin
and caveolin-1 [18,19]. The interaction between 4F2hc and CD147
(highly glycosylated form) regulates energetic metabolism through
AMP-activated kinase likely by coordinating transport of amino acids
and lactate [16]. CD147 stimulates the production of several matrix
metalloproteinases (MMPs) and angiogenic factors (as VEGF) by
surrounding ﬁbroblasts and tumor cells [20]. Furthermore, MMP expres-
sion is often increased in cancer and has been correlated with tumor
invasiveness and metastasis through degradation of the extracellular
matrix (ECM) thus facilitating the colonization of healthy tissues by
malignant cells [21,22]. In fact, MMP-2 and -9 have been proposed as
prognostic survival markers to predict tumor recurrence in several can-
cers [23].
Here we report that silencing of 4F2hc reduces cell motility and
MMP-2 levels and activity (withoutmodiﬁcation of CD147 expression),
and increase extracellular galectin-3 levels. These effects are conse-
quence of a down-regulation of several signaling pathways, and eventu-
ally lead to an impairment of in vivo tumorigenesis.
2. Materials and methods
2.1. Cell culture
HeLa human cervical carcinoma cells (CCL2, ATCC) were cultured in
DMEM (Dulbecco's modiﬁed Eagle's medium) containing 4.5 g/l
glucose and supplemented with 10% heat-inactivated fetal calf serum,
penicillin (100 IU/ml), streptomycin (100 μg/ml) and 2 mMglutamine.
Cells were maintained in a humidiﬁed atmosphere of 5% CO2 at 37 °C
and were routinely subcultured by trypsinization [0.05% trypsin, 0.02%
EDTA].
2.2. Antibodies
The following antibodies against human proteins were used for
Western blot: CD98 (C-20), galectin-3 (H-160), p21 (C-19) (Santa
Cruz Biotechnologies, Heidelberg, Germany), CD147 (anti-EMMPRIN;
Zymed/Invitrogen-Life Technologies, Alcobendas, Spain), CD29
β1-integrin, β-catenin, caveolin (BD Transduction, San Agustín de
Guadalix, Spain), MMP-2 (Calbiochem, Madrid, Spain), Akt, p-Akt,
ERK1/2, p-ERK1/2, FAK, p-FAK (Cell Signaling, Danvers, MA), GSK3β,
p-GSK3β (Thermo Scientiﬁc, Alcobendas, Spain), vinculin (hVIN1),
β-tubulin I (Sigma, Alcobendas, Spain), and lamin B1 (MBL, Woburn,
MA). Anti-GFP was kindly provided by Dr. Rodríguez-Crespo
(Complutense University, Madrid, Spain) [24]. For immunocytochem-
istry and ﬂow cytometry, the primary antibodies were: anti-4F2hc
(FG1/8), anti-CD29 (TS2/19) (kindly provided by Dr. Sánchez-Madrid,
Hospital de la Princesa, Madrid, Spain), or anti-CD147 (anti-EMMPRIN
8D6, Santa Cruz Biotechnologies). The following secondary antibodies
were used: rabbit anti-goat IgG-HRP, Texas-Red donkey anti-mouse,
FITC donkey anti-mouse, FITC goat anti-rabbit (Jackson Immunoresearch
Laboratories, Suffolk, UK), alexa-647 donkey anti-mouse IgG (Invitrogen-
Life Technologies), goat anti-rabbit IgG-HRP (Bio-Rad, Alcobendas, Spain),
or goat anti-mouse IgG-HRP (Pierce/Thermo Scientiﬁc).
2.3. 4F2hc silencing
Silencing of 4F2hc expression in HeLa cells was carried out by
miRNA using a lentiviral vector system derived from HIV. An artiﬁcial
miRNA was designed by using BLOCK-iT™ iRNA Designer Software
with NM001013251 sequence from 4F2hc (Invitrogen, Life Technolo-
gies) to avoid 4F2hc-mRNA translation. Double-stranded oligonucleo-
tides encoding miRNA 947 precursor, or a scrambled sequence
(negative control), were cloned into pcDNA™6.2-GW/EmGFP-miR
expression vector (Invitrogen-Life Technologies). The miRNA 947 orthe negative control expression cassettes were transferred into the
lentiviral expression plasmid pLenti6/V5DEST by means of Gateway
recombination technology using the pDONR221 vector as an intermedi-
ary (Invitrogen-Life Technologies).
To obtain viral particles, the lentiviral expression vectors were
co-transfected with pCMVδR8.74 (packaging system) and pMDG.2
(envelope system) vectors into HEK 293T cells (ATCC) using the
calcium phosphate method. After incubation at 33 °C, culture media
with viral particles were collected. These media were ﬁltered and con-
centrated by sucrose gradient centrifugation. To titrate the obtained
viral particles, HeLa cells were seeded on 24-well plates and subse-
quently infected with different dilutions of concentrated viruses. Cells
were trypsinized, viral particles were inactivated by addition of 3%
paraformaldehyde, and EmGFP expression was determined by ﬂow
cytometry. HeLa cells were then transduced (multiplicity of
infection = 1) and the infected population was selected by FACS
(Fluorescence-activated cell sorting) and blasticidin treatment. Experi-
ments were always carried out with cells with ~80% 4F2hc silencing.
2.4. Cell proliferation, adhesion and spreading assays
Cells were plated out in 5% FBS medium and, after 24 h, serumwas
removed. One day later cells were treated with 20 μg/ml laminin
(LN), ﬁbronectin (FN) or collagen type-I or type-IV, serum (2–20%)
or PMA (0.1–1 μM) for 4 h at 37 °C in presence of 0.9 μCi [3H] thymi-
dine per well (Amersham, Buckinhamshire, UK). Afterwards, media
was removed and cells were washed, treated with 5% trichloroacetic
acid/PBS for 15 min at room temperature and washed twice with
cold ethanol. Finally, cells were solubilized with 0.1 N NaOH/1% SDS
and [3H] thymidine was counted on a LS3801 liquid scintillation
counter (Beckman Coulter, Brea, CA).
Cell adhesion assays were performed in 96-well microtiter plates
coated with laminin, ﬁbronectin, type-I or type-IV collagen, or BSA
(5 μg/ml) overnight at 4 °C. Afterwards, plates were washed three
times in PBS/50 μg/ml kanamycin, and non-speciﬁc-binding sites
were blocked by addition of 0.5% BSA (w/v) in PBS for 2 h at 37 °C.
Cells (105 cells/well) were seeded in serum-free medium and incu-
bated at 37 °C from 10 min up to 24 h. Non-adherent cells were re-
moved with PBS and attached cells were ﬁxed with acetone/
methanol (1:1) for 10 min at 4 °C. Cell adhesion was determined
after staining with 0.5% (w/v) crystal violet in 20% (v/v) methanol
for 30 min at room temperature and solubilization with 0.5% (v/v)
SDS; absorbance was measured at 550 nm. The attachment of cells
to wells coated with 1 mg/ml poly-L-Lys and ﬁxed with 20% (v/v)
glutaraldehyde before aspiration was deﬁned as 100% of adhesion.
Spreading of HeLa cells was carried out on coverslips coated with
laminin, ﬁbronectin or BSA (5 μg/ml) in DMEM containing 1% (w/v)
BSA. After 1 h cells were washed with 100 mM PIPES pH 6.8, 1 mM
EGTA, 2 mM MgCl2 (PEM buffer) containing 4% (v/v) polyethylene
glycol (Sigma) and were permeabilized using 0.5% (v/v) Triton
X-100 in PEM buffer for 90 s at room temperature. Once washed,
cells were ﬁxed (2% p-formaldehyde) and stained for β-tubulin
using a Texas-Red labeled secondary antibody. All antibody incuba-
tions were performed at 37 °C and preparations were visualized
using an Axioplan 2 microscope (Zeiss).
2.5. Western blot
Total cell protein extracts were obtained by solubilization of the
monolayers in lysis buffer (10 mM Tris pH 8.0, 140 mM NaCl and 2%
Triton X-100) containing protease and phosphatase inhibitors (PMSF,
aprotinin, pepstatin A, leupeptin, Na3VO4, NaF, β-glycerophosphate,
dithiothreitol, all at 1 μM ﬁnal concentration). Nuclear and cytosolic ex-
tracts were obtained as described elsewhere [25,26]. Protein concentra-
tion was determined using the DC Protein assay (Bio-Rad). Cell lysates
were resolved by SDS-PAGE after heat denaturing in presence of 5%
2047A. Santiago-Gómez et al. / Biochimica et Biophysica Acta 1833 (2013) 2045–2056β-mercaptoethanol. Proteins were transferred to nitrocellulose mem-
branes and analyzed by Western blot as described elsewhere [27]. De-
tection was performed using the Amersham ECL Western blot system
according to the manufacturer's protocol (GE Healthcare, Barcelona,
Spain) on a LAS-3000 detector (Fujiﬁlm, Düsseldorf, Germany) and den-
sitometric analyses were carried out using Multi-Gauge v3.0 software
(Fujiﬁlm). Vinculin and lamin B1 were used as cytosolic and nuclear ex-
tracts loading controls, respectively.2.6. Zymography and quantiﬁcation of MMP-2 activity
Conditionedmedia fromHeLa cells were obtained from subconﬂuent
cultures (60–70% conﬂuence) grown in serum-free medium for 24 or
48 h, and were concentrated by centrifugation using 10000 MWCO
Vivaspin concentrators (Sartorius, Göttingen, Germany). MMP-2 and
MMP-9 activities were determined through zymography as previously
described [28]. Brieﬂy, samples (5 μg protein) were prepared as de-
scribed above for SDS-PAGE analysis, but in the absence of thiol reducing
agents, and were resolved at 4 °C in polyacrylamide gels (10%)
copolymerized with 0.2% gelatin and 0.1% SDS. Gels were washed twice
in 50 mM Tris pH 7.4, 2.5% Triton X-100 at room temperature for
30 min to remove SDS, followed by washing twice in 50 mM Tris pH
7.4, for 10 min. Then, incubation at 37 °C in 50 mM Tris pH 7.5, 0.15 M
NaCl, 10 mM CaCl2, 0.1% Triton X-100 and 0.02% NaN3 was carried out
for 24–72 h. Finally, the gels were stained with Coomassie blue (R250)
and washed afterwards with 7.5% (v/v) acetic acid containing 20%
methanol to visualize MMP activity.
Quantiﬁcation of MMP-2 activity was performed using the
SensoLyte 490 MMP-2 Assay kit (AnaSpec, Fremont, CA) according
to manufacturer's instructions. The cleavage of a ﬂuorescence
resonance energy transfer (FRET) peptide was monitored at
490 nm/520 nm (excitation/emission wavelengths) in a ﬂuorescence
plate reader (Fluostar Optima; BMG LabTech, Offenburg, Germany).
Batimastat (BB-94; Tocris Bioscience, Ellisville, MO), a synthetic
MMP competitive inhibitor, was used to inhibit MMP-2 activity in
conditioned media. Its peptide backbone binds to the MMP and the
hydroxamic acid chelates the zinc ion located at the active site,
thereby causing an inactivemetalloproteinasewithout affecting its syn-
thesis [29]. Conditioned media from HeLa cells treated with Batimastat
at 5, 10 or 20 μM for 24 hwere processed for protein levels andMMP-2
activity. DMSO (Sigma) was used as vehicle control.2.7. Immunoprecipitation
Immunoprecipitation was carried out after a mild crosslinking
procedure [30]. Brieﬂy, cells were ﬁxed in 2% p-formaldehyde
(Calbiochem) for 7 min at room temperature with mild agitation.
Then, cells were centrifuged at 1800 g for 3 min, resulting in 10 min
total formaldehyde exposure. After supernatant removal, the
crosslinking reaction was quenched by addition of ice-cold 1.25 M
glycine/PBS to the pellet; cells were spun, washed in 1.25 M gly-
cine/PBS and lysed. Total lysates (approx. 250 μg) in buffer containing
2% Triton X-100 were pre-cleared twice through 4B-Sepharose at 4 °C
for 1 h to reduce non-speciﬁc binding of proteins. Then, 5 μg of the
corresponding antibody [anti-galectin 3, control normal mouse IgG
(ProSci incorporated, Poway, CA), or ascitic ﬂuid anti-4F2 C13
(HB-22) from ATCC] was added to the sample and incubated
overnight at 4 °C under agitation. Afterwards, 20 μl of protein
A-Sepharose beads in lysis buffer was added and the mixture was in-
cubated at 4 °C under rotary agitation for 2 h, centrifuged and
washed 3 times in lysis buffer. Finally, the beads were resuspended
in SDS-PAGE loading buffer containing 5% β-mercaptoethanol, boiled
10 min at 99 °C to denature the samples and reverse cross-links [30],
centrifuged and the supernatants were analyzed by Western blot.2.8. Sucrose gradient
Conﬂuent cells were collected and lysed in 25 mM MES pH 7.0,
0.15 M NaCl (MES buffer) containing 1% Triton X-100 and protease
inhibitors, and passed through a 25-gauge needle at least 5 times at
4 °C. After centrifugation for 10 min at 1500 g, the supernatant was
adjusted to 40% sucrose by addition of 80% sucrose in MES buffer
and placed at the bottom of an ultracentrifuge tube. A 5/30% discon-
tinuous sucrose gradient was formed above (both sucrose solutions
in MES buffer) and centrifuged at 4 °C in a SW65 rotor (Beckman
Coulter) at 35,000 rpm overnight. Fractions were then collected
from the bottom of the tube and protein was precipitated with
acetone/methanol (1:1) for 2 h at−20 °C. After centrifugation, sedi-
ments from each fraction were analyzed by SDS-PAGE and Western
blot.2.9. Flow cytometry
Cells were harvested by trypsinization, washed twice with PBS
and ﬁnally resuspended in PBS containing 0.02% (w/v) sodium azide
and 0.1% (w/v) BSA. After incubation with the speciﬁc primary anti-
body for 1 h at room temperature, cells were washed 3 times with
the former buffer followed by labeling with Alexa 647 conjugated an-
tibodies for 45 min at room temperature in darkness and washed at
least twice. Analyses were performed in a FACScan cytometer
(Becton-Dickinson, San Jose, CA) as previously reported [31,32].2.10. Immunocytochemistry
Cells were seeded on coverslips and, after 2 days incubation, were
washed with PBS and ﬁxated with 3.7% p-formaldehyde. After wash-
ing twice, coverslips were incubated with PBS containing 1% (w/v)
BSA for 20 min at room temperature to block unspeciﬁc binding of
the antibodies, washed again, and incubated with the ﬁrst antibody
in a humidiﬁed chamber for 1 h at 37 °C. Secondary ﬂuorescent-
labeled antibody incubation was carried out for 1 h at 37 °C in the
dark. Finally, samples were washed and mounted in ProLongGold
(Invitrogen-Life Technologies) and examined with a Leica DM IRE2
confocal scanning microscope.2.11. In vivo tumorigenicity
Athymic BALB/c nude male mice (6–8 week-old, Harlan Ibérica,
Barcelona, Spain) were used to assess in vivo tumorigenicity of
HeLa cells (control or 4F2hc-silenced). Three independent in vivo
experiments were carried out with 8 mice per group; cells for
each experiment were selected by FACS and blasticidin resistance,
and 4F2hc expression was always checked by Western blot before
injection. Cells (6 × 105) were resuspended in PBS and injected
subcutaneously on both sides of the lumbar region. Mice were sur-
veyed daily to determine when tumors ﬁrst became apparent upon
visual inspection (latency time; size >1 mm) and tumor sizes were
then measured every 4–5 days. Tumor size was calculated by
measuring the dimensions of the tumor mass (average of the two
right-angle diameters, the largest and its perpendicular) with a
Vernier caliper, as previously described [32,33], and volume was
calculated as (4π/3)x(size/2)3. After necropsy, tumors were ex-
cised, cleaned of surrounding tissue and weighed. 4F2hc expression
in tumor and in cell extracts was analyzed by Western blot as de-
scribed before. All procedures involving animals were performed
with the approval of the Complutense University Animal Experi-
mentation Committee according to Spanish and European ofﬁcial
regulations.
Fig. 1. Silencing of 4F2hc in HeLa cells. 4F2hc expression of transduced cells was deter-
mined after FACS and antibiotic selection by Western Blot (A), ﬂow cytometry (B; MFI
values are indicated), and confocal microscopy (C).
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The in vitro wound healing assay was carried out essentially as de-
scribed elsewhere [34]. Brieﬂy, cells were plated at 1.5 × 104 cells/cm2
in 6-well plates and allowed to grow until 85–90% conﬂuence. Two par-
allel lineswere drawn at the bottom of thewells with amarker as an op-
tical reference and three scratchwoundsweremade using a 200 μl pipet
tip on the monolayers perpendicular to the marker lines drawn before.
Cellswerewashed twicewith PBS to removeﬂoating cells and further in-
cubated in normal growth medium. Wounds were observed regularly
since time 0 until the wound was completely closed (~24 h) using
phase contrast on a Nikon Eclipse TE2000-U microscope (10× magniﬁ-
cation). Images (n = 4) were taken of both areas ﬂanking the intersec-
tions of the wound and the marker lines at different time points. The
invaded area of each sample compared to time 0 was calculated from
digitalized pictures.
2.13. Signaling array
Cignal Finder Reporter Array (SABiosciences-Qiagen Iberia, Las
Matas, Spain) was used to analyze whether 4F2hc silencing affected
the main signaling pathways related to cancer. Each 96-well plate
contained 10-dual-luciferase reporter assays (besides positive and
negative controls), where each reporter is a mixture of an inducible
transcription factor responsive construct (tandem repeats of a
speciﬁc transcriptional response element joined to ﬁreﬂy luciferase)
and a constitutively Renilla luciferase construct. The assays were de-
veloped following the manufacturer's recommendations using Escort
IV (Sigma) as reagent for reverse transfection and Dual-Glo Luciferase
Assay System (Promega, Madrid, Spain) to detect luciferase activity in
a Fluostar Optima ﬂuorescence plate reader. Fireﬂy luciferase data
were normalized to the corresponding transfection efﬁciency by
using the Renilla luciferase activity of each well.
2.14. Statistical analysis
The normal distribution of data was determined by the Kolmogorov–
Smirnov test. ANOVA analyses and Student's t-tests (two-tailed) were
carried out using SigmaPlot v12.3 (Systat Software, Erkrath, Germany).
Power analyses were carried out using either SigmaPlot or G*Power
3.1.6 [35]. Statistical signiﬁcance was considered to be achieved at the
p b 0.05 level.
3. Results
4F2hc overexpression in tumors and in tumor-derived cell lines
has been associated with malignant transformation and has been pro-
posed as a potential marker of malignancy. Tumor-associated 4F2hc
overexpression (around 2-fold) was here observed by using a tissue
array, showing 4F2hc staining of normal and tumor sections from
ovary and uterus (Supplementary Fig. 1).
3.1. 4F2hc silencing in HeLa cells
To analyze the role of 4F2hc in tumorigenicity, we stably repressed
its expression in HeLa cells using a designed miRNA (named 947) by
means of a HIV-derived lentiviral system. Once cells were transduced
and selected as described in Section 2, 4F2hc expression was assessed
(Fig. 1). A signiﬁcant reduction (around 80%) in protein levels was ob-
served for HeLa-947 cells compared to control or scramble ones
(HeLa-scr) (Fig. 1A). Non-transduced HeLa cells did not show
EmGFP expression (marker of infection), whereas 4F2hc expression
on the plasma membrane was similar to that observed in HeLa-scr
cells as demonstrated by ﬂow cytometry; mean ﬂuorescence intensi-
ty (MFI) values were 254 and 257, respectively (Fig. 1B). However,
4F2hc expression on HeLa-947 cell surface was reduced to a MFIvalue of 17. Immunostaining also conﬁrmed 4F2hc silencing in
HeLa-947 cells, proving the efﬁciency of this miRNA to reduce 4F2hc
expression (Fig. 1C).
3.2. Repression of 4F2hc impairs in vivo tumorigenicity
In vivo tumorigenicity of transduced HeLa cells (scramble and
knock-down cells) was determined after subcutaneous injection into
athymic BALB/c nude mice, and tumor growth was monitored for
24 days (Fig. 2A). Tumor formation was ﬁrst observed in HeLa-scr 4–
6 days after injection, whereas a signiﬁcant delay in tumor appearance
occurred with HeLa-947 cells (>10 days until tumors began to be mea-
surable; Supplementary Fig. 2 & Fig. 2A). However, tumor growth was
observed afterwards, although with a different growth rate when
tumor volume is considered (Fig. 2A), indicating the existence of a
delay in the lag phase of silenced cells. After 24 days, signiﬁcant
differences were observed in the aspect of mice and in the size of the tu-
mors after surgical excision (Fig. 2A, insets), which was also evident in
tumor weight. Tumors derived from HeLa-947 cells showed around
33% reduction in weight compared with those from non-silenced HeLa
cells (1.8 ± 0.4 vs. 2.7 ± 0.5 g, respectively, p b 0.05; Supplementary
Fig. 2). No metastatic nodes were found during post-mortem analysis
of tumor-bearing mice.
4F2hc and GFP expression was checked on HeLa-scr and HeLa-947
cells before injection into nudemice to conﬁrm that 4F2hc remained si-
lenced (~80%) (Fig. 2B). Cells from HeLa-947 tumors still showed de-
creased expression of 4F2hc, but silencing was reduced to just 23–25%
compared to the corresponding cells from HeLa-scr tumors (Fig. 2B,
C). Expression of 4F2hc was stronger in the inner layers of the tumors
compared to the outer ones. Although GFP expression in HeLa-scr and
-947 injected cells was almost identical, cells derived from both types
of tumors showed a signiﬁcant decrease in its expression (p b 0.01),
that was even larger in HeLa-947 derived tumors. The decrease in
4F2hc silencing and in GFP levels could arise from the progressive in
vivo loss of expression of the EmGFP-scr and EmGFP-miR947 cassettes
which are under control of the lentiviral promoter.
Fig. 2. In vivo tumorigenicity of HeLa-scr and HeLa-947 cells. Tumorigenicity was
assessed by subcutaneous injection into nude mice. Tumor volumes (A) were mea-
sured at designated time points and data represent mean values (±s.d.) of triplicate
experiments using 8 mice per group. ANOVA analysis revealed a signiﬁcant different
evolution of the tumor growth in mice from the HeLa-scr and HeLa-947 groups. Mice
were sacriﬁced 24 days after injection and tumors were excised, carefully cleaned of
surrounding tissue and weighed (B) Western blots of 4F2hc and GFP in HeLa-cells be-
fore injection (left) or in the outer and inner layer of the tumors developed in nude
mice 24 days after injection of the cells (right) are shown. Densitometric analyses
were carried out (C) and the mean values (±s.d.) of 4F2hc and GFP expression are
represented normalized to that obtained in HeLa-scr cells before injection referred to
vinculin expression as control of even protein loading (*, p b 0.05; **, p b 0.01).
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spreading
The effect of different ECM components (laminin, ﬁbronectin or col-
lagen type-I or IV) or mitogens (such as serum or PMA) in cell prolifer-
ation was assessed by measuring the incorporation of [3H] thymidine
into DNA (Fig. 3). 4F2hc-silenced cells showed a 29% decrease in DNA
synthesis in the absence of serum compared to control or HeLa-scr
cells. The mitogenic activity of control, scramble and silenced HeLa
cells was not affected by the presence of ECM components, but asigniﬁcant increase was observed after treatment with serum and, to a
lower extent, with PMA. Despite this response, HeLa-947 cells showed
a lower response to serum and PMA than control and scramble ones
did. Interestingly, under standard culture conditions, p21 expression
was signiﬁcantly increased in HeLa-947 cells (Fig. 3, right panel insert),
a fact that could be related with the observed decrease in DNA
synthesis.
Cell adhesion and spreading to different components of ECM were
also analyzed. Laminin, ﬁbronectin, type-I and type-IV collagens signif-
icantly increased cell attachment compared to that obtained in the
presence of bovine serum albumin (BSA, negative control) (Supplemen-
tary Fig. 3A). However, there were not signiﬁcant differences between
the attachment of HeLa-scr and HeLa-947 cells over each substrate. In
addition, only a slight difference in morphology was observed after
assessing cell spreading on laminin or ﬁbronectin. Silenced cells showed
a bipolar spindle shape while control ones were more polygonal, mainly
on ﬁbronectin, short time after seeding (Supplementary Fig. 3B).
3.4. 4F2hc-associated proteins and MMP-2 expression in HeLa-silenced
cells
Confocal microscopy showed co-localization of 4F2hc with
β1-integrin and CD147, as well as co-localization between them on
the plasma membrane of HeLa cells (Fig. 4A). These results strongly
suggest the association of the three proteins in HeLa cells, probably
forming a multimolecular complex which regulates integrin signaling.
The expression ofβ1-integrin, CD147 and 4F2hcwas analyzed in the
cell membrane by ﬂow cytometry (Fig. 4B) and byWestern blot in total
cell lysates (Fig. 4C) in control and transduced HeLa cells. In addition,
the intracellular levels of galectin-3 (physiological ligand of 4F2hc)
and matrix metalloproteinase-2 (MMP-2, which is induced by CD147)
were also analyzed. 4F2hc silencing came along with a decrease in cel-
lular MMP-2 expression (42%, p b 0.01), whereas β1-integrin, CD147
and galectin-3 protein levels were not signiﬁcantly altered. The interac-
tion between 4F2hc and galectin-3 was conﬁrmed in HeLa cells by
co-immunoprecipitation of 4F2hc with anti-galectin-3 antibodies and
by the reciprocal immunoprecipitation of galectin-3 with 4F2hc anti-
bodies (Fig. 4D).
It has been reported that the interaction of 4F2hc with β1-integrins
may occur in lowdensity lipidmicrodomains (rafts), usually considered
as signaling platforms [36]. Toﬁnd outwhere β1-integrin/4F2hc/CD147
association takes place within the plasma membrane of HeLa cells, we
performed sucrose gradients to isolate membrane microdomains
according to their density. Expression of β1-integrin, CD147 and
4F2hc was determined by Western blot together with detection of
caveolin as marker of low-density caveola/rafts (Fig. 4E). The former
proteins were present in the dense fractions of a sucrose gradient (frac-
tions 1 to 4), although a minor amount of β1-integrins was also located
in the light fractions where caveolin was detected (ﬂotation control;
fractions 7 to 9). According to these results, CD147/4F2hc/β1-integrin
interaction did not take place in raft-like membrane domains in HeLa
cells. In addition, we have conﬁrmed that galectin-3 appears in the
same fractions as 4F2hc within the sucrose gradient (Fig. 4E).
3.5. 4F2hc silencing modulates MMP-2 expression and activity
As shown before, repression of 4F2hc in HeLa cells led to a decrease
in total cell levels of MMP-2, but did not affect CD147 expression
(Fig. 4C). Taking into account that MMP-2 is secreted, its levels and ac-
tivity were analyzed in conditionedmedia from control and transduced
HeLa cells (Fig. 5). A signiﬁcant drop (84%, p b 0.01) in MMP-2 levels
was observed in conditioned media from 4F2hc silenced cells (Fig. 5A,
upper panels, and 5B, left). Moreover, gelatin zymography (Fig. 5A,
lower panels) and subsequent densitometric analysis (Fig. 5B, right)
showed a decrease of bothMMP-2 pro-enzyme and active forms. Quan-
tiﬁcation of MMP-2 activity using a ﬂuorogenic assay showed a ~3-fold
Fig. 3. Inﬂuence of 4F2hc silencing inmitogen-mediated proliferation of HeLa cells. Proliferation assays were carried out bymeasuring [3H]thymidine incorporation in serum-freemedia
(control, black bars) supplemented with 20 μg/ml laminin (LN), ﬁbronectin (FN) or collagen type-I or type-IV (Col I or Col IV). Cultures in presence of serum (2–20%) or PMA (0.1–1 μM)
were also used as mitogens. Experiments were carried out in triplicate with 3–6 wells per mitogen, and data represent mean values (±s.d.; ##, p b 0.01 in comparisons of
transduced-cells controls with that of non-transduced HeLa cells; *, p b 0.05; **, p b 0.01, in comparisons with the corresponding controls). The insert corresponds to a representative
Western blot analysis of p21 in control and transduced HeLa cells growing in standard culture medium. Densitometric analyses from three different blots with two different amounts
of total loaded protein reveal no signiﬁcant differences in p21 levels between control andHeLa-scr cells; HeLa-947 cells show a 2.54-fold increase in p21 levels (±0.11; p b 0.01). Vinculin
expression was used as loading control.
Fig. 4. Expression of 4F2hc-associated proteins. (A) Co-localization of 4F2hc with β1-integrin and CD147 was analyzed by confocal microscopy. Expression of 4F2hc-associated pro-
teins was determined by ﬂow cytometry (B) and by Western blot of whole-cell lysates (C) using vinculin (vinc.) as even protein loading control. (D) Detection of 4F2hc and
galectin-3 in whole-cell lysates immunoprecipitated using anti-galectin-3 or anti-4F2hc antibodies (IgG, non-speciﬁc antibody). (E) Localization of β1-integrins, CD147, 4F2hc
and galectin-3 within cell membrane fractions with different ﬂoatability in sucrose gradients. Caveolin was used as marker of low density raft fractions.
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control or HeLa-scr cells (Fig. 5C). MMP-9 was detected by gelatin
zymography, but its levels were quite low compared to MMP-2
(≤5-fold), as reported for HeLa cells [37,38]; silencing of 4F2hc also in-
duced a 50% decrease in its levels.
Taking into account that galectin-3 is a potential substrate of
MMP-2, we analyzed its levels in conditioned media (Fig. 5A) despite
its expression in total lysates was not affected after 4F2hc-silencing
(Fig. 4C). An extracellular accumulation of galectin-3 in conditioned
medium from silenced cells (more than 6-fold) was found in compari-
son with media from control or HeLa-scr cells. Such accumulation
could be the consequence of decreased MMP-2 activity in the extracel-
lular milieu in HeLa-947 cells. To conﬁrm this hypothesis, the effect of
Batimastat, a synthetic MMP inhibitor, was analyzed in conditioned
media from control HeLa cells (Fig. 6). Although MMP-2 protein levelsFig. 5. Secretion of MMP-2 and galectin-3 in HeLa control and 4F2hc-silenced cells. Con-
ﬂuent cells were maintained in serum-free medium for 48 h and conditioned media
were collected. (A) Western blot analysis of galectin-3 and MMP-2 levels in conditioned
media (upper panels); gelatin zymography showing the expression/activity of MMP-2
and, to a much lower extent, MMP-9 (lower panel). (B) Densitometric analysis of the
Western blots (left) and zymography (right); data correspond to the analysis of 3–4
blots or zymograms with samples from independent experiments and with different
amounts of protein loaded per lane. Densitometric analysis of the zymogram includes
ﬁrst the relative expression of pro-MMP-9, pro-MMP-2 and enzymatically processed
MMP-2 in control HeLa cells (normalized versus the bandof pro-MMP-2), and also the rel-
ative expression of these proteins in control, scramble- (scr) and 947-transduced cells
normalized versus the corresponding band in control cells. (C) Quantiﬁcation of MMP-2
activity by cleavage of a FRET peptide. Data correspond to mean values (±s.d.) from
three independent experiments with triplicate samples (**, p b 0.01).
Fig. 6. Inﬂuence of MMP-2 activity inhibition on galectin-3 levels in conditioned media
from HeLa cells. Conﬂuent cells were maintained in serum-free medium for 24 h in the
presence of different concentrations of Batimastat. (A) Western blot analysis of
galectin-3 and MMP-2 levels in conditioned media. (B) Quantiﬁcation of MMP-2 activity
by cleavage of a FRET peptide. Data correspond to mean values (±s.d.) from three inde-
pendent experiments with triplicate samples. (C) Densitometric analysis of galectin-3
levels; data correspond to the analysis of three blots with samples from independent ex-
periments and with different amounts of protein loaded per lane (**, p b 0.01).in the extracellular milieu were not modiﬁed by the presence of
increasing concentrations of Batimastat (Fig. 6A), quantiﬁcation of its
activity using a ﬂuorogenic assay showed a signiﬁcant decrease in a
dose-dependent manner (Fig. 6B; p b 0.01). This decrease was accom-
panied by a parallel increase in extracellular galectin-3 as observed by
Western blot and subsequent densitometric analysis (Fig. 6A, C;
p b 0.01).
3.6. 4F2hc facilitates cell motility
Gelatinase activity is usually associated with motility and invasive-
ness of malignant cells. As 4F2hc-silenced cells showed lower expres-
sion and activity of both gelatinases MMP-2 and MMP-9, we studied
whether cell motility of HeLa cells was affected by silencing. In vitro
wound healing assay (Fig. 7) revealed that the initial cell-free scratches
(around 500 μm in width) were rapidly closed by HeLa control and
mock-transduced cells. After 9 h, around 80% of the wound was
re-populated by control cells, being completely closed after 24 h.
4F2hc-silenced cells showed a signiﬁcant delay in wound healing com-
pared to controls as only ~50% of the woundwas re-populated after 9 h
and ~20–25% remained cell-free after 24 h.
3.7. Repression of 4F2hc down-regulates integrin signaling pathways
Interaction of 4F2hc with β1-integrins modulates integrin signaling
pathways, including ERK (Extracellular signal-Regulated Kinases), PI3K,
FAK, Src and Rho GTPases [5,39]. In addition, survival signals activate
integrin-dependent Akt phosphorylation at Ser473 induced by PI3K
leading to proliferation [40]. Thus, signaling events downstream of
integrins were considered after 4F2hc silencing in HeLa cells (Fig. 8).
Activation of Akt was assessed after allowing cells to adhere for
30 min to different ECM substrates (Fig. 8A). Cell attachment to culture
plastic, ﬁbronectin or laminin promoted Akt activation, being this
effect lower in HeLa-947 cells. Moreover, Akt phosphorylation in
non-transduced cells was stronger after interaction with ﬁbronectin
Fig. 7. Cell motility analysis of 4F2hc-silenced cells. Scratch wounds were made on near-conﬂuent HeLa cell cultures (control, HeLa-scr or HeLa-947). Images were taken at different time
points untilwoundswere completely closed. The averagewoundwidth (±s.d.)was calculated from the data from three independent experiments as described under Section 2 (**, p b 0.01).
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in HeLa-947 cells. Moreover, we checked phosphorylation of a second
downstream target of Akt signaling (GSK-3β, glycogen synthase
kinase-3β), which mediates phosphorylation of different substrates, as
β-catenin, triggering their degradation by the proteasome [41,42].
GSK-3β phosphorylation at Ser9 by Akt reduces its activity, promoting
β-catenin stabilization and consequent signaling activation. 4F2hc si-
lencing strongly impaired GSK-3β phosphorylation/inactivation
(Fig. 8B, left panels), whereas total levels of GSK-3β (and both total
and phospho-GSK-3α) were not altered. A concomitant reduction of
β-catenin protein levels was also observed in total extracts of silenced
cells (Fig. 8B, left panels), not being due to nuclear accumulation as
both cytoplasmic and nuclear levels of β-catenin were reduced
(Fig. 8C). Therefore, 4F2hc-silencing impairs Akt activation, remaining
GSK-3β active and triggering degradation of β-catenin.4F2hc-silencing also triggered a strong reduction in FAK phosphory-
lationwhile total levelswere not affected (Fig. 8B, right panels) strongly
suggesting a role of 4F2hc in this integrin dependent signaling process.
In addition, the phosphorylation status of ERK1/2 in control and
4F2hc-silenced HeLa cells was analyzed (Fig. 8B, right panels). A signif-
icant decrease in the phosphorylation status of ERK1/2 was observed
after 4F2hc silencing. Akt, FAK, GSK-3α/β and ERK1/2 total levels did
not change, conﬁrming that 4F2hc knock-down only modiﬁed the
phosphorylation/activation of pre-existing proteins. Therefore, 4F2hc
might act as a positive modulator enhancing intracellular integrin
signaling.
A signaling pathway arraywas also carried out to further analyze the
effects of 4F2hc repression on main signaling pathways related to can-
cer. The array conﬁrmed that 4F2hc silencing signiﬁcantly reduced
ERK signaling (2.5-fold). Furthermore, decreased basal activation was
Fig. 8. 4F2hc silencing impairs integrin signaling. (A) Akt activation was assessed after
allowing cells to adhere for 30 min to FN, LN or plastic (P) detecting its phosphorylation
at Ser473. (B) Activation status and/or expression of Akt-downstream targets, as GSK3β,
and different proteins involved in integrin signaling, such as β-catenin, FAK or ERK1/2,
were analyzed by Western blot in control and transduced cells. (C) β-catenin expression
was determined in cytoplasmic and nuclear extracts of HeLa control, scr and 947 cells.
Vinculin and lamin B1 were used as loading controls for total/cytoplasmic and nuclear
proteins, respectively. (D) Signaling pathway array based on tandem repeats of a speciﬁc
transcriptional element for each pathway joined to ﬁreﬂy luciferase as reporter gene was
carried out. Data were normalized to the corresponding transfection efﬁciency by Renilla
luciferase activity of eachwell. Mean values (±s.d.) from three independent experiments
with quadruplicate samples per pathway are shown (*, p b 0.05; **, p b 0.01).
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naling via HIF-1α (3.6-fold), NFκB (1.7-fold) and Myc/Max (2.1-fold),
among other minor modiﬁcations in pathways with low basal activa-
tion (Fig. 8D). Altogether, these data suggest that integrin-dependent
processes as cell survival and proliferation might be compromised
after 4F2hc repression in tumor cells.
4. Discussion
Different approaches have been carried out to understand the phys-
iological role of 4F2hc in tumorigenicity. It has been described thatformation of teratocarcinomas is impaired in 4F2hc-null ES cells,
whereas overexpression of 4F2hc in NIH3T3 cells leads to tumor devel-
opment [5,7]. Here, we have stably silenced 4F2hc expression in HeLa
cells using miRNA. First, we assessed the in vivo tumorigenic potential
of 4F2hc knock-down cells in nudemice. Silencing of 4F2hc strongly im-
paired in vivo tumorigenicity inducing a signiﬁcant delay in tumor cell
implantation which resulted in a reduction in tumor weight. Therefore,
the expression of 4F2hc seems to be crucial not only for the initial stages
of tumor cell implantation, but also is critical for cell survival and
proliferation. However, HeLa-947 cells eventually lead to tumor growth.
This could arise from the initial presence of a minor non-silenced cell
population or well to the loss of 4F2hc silencing. Our data point out to-
wards the second possibility. It has been reported that retroviral pro-
moters, as the one that we have used to control the expression of the
EmGFP-miR947 cassette, can be epigenetically silenced by the trans-
duced cells after long-term culture [43,44]. In fact, we have detected
that HeLa-947 cells gain 4F2hc and lose GFP expression after
long-term culture maintaining blasticidin resistance, which is under
control of a eukaryotic promoter. Thus, it is highly probable that the
concomitant expression of both miR947 and GFP may be silenced dur-
ing the in vivo tumor growth, in agreement with 4F2hc and GFP levels
detected in the excised tumors.
4F2hc-silenced cells in vivo may have an impaired response to
host growth factors essential for the initial stages of tumor implanta-
tion and proliferation. This is supported by the fact that an inefﬁcient
proliferation has been reported for 4F2hc non-expressing cells: i)
4F2hc deletion in vascular smooth muscle cells reduced intimal hy-
perplasia after arterial injury suppressing proliferation and inducing
their apoptosis [10], and ii) 4F2hc deletion in lymphocytes abrogates
clonal proliferation of B and T cells, respectively [45,46]. In addition,
we have observed that repression of 4F2hc expression impairs cell
proliferative response to growth factors present in fetal bovine
serum, enforcing the role of 4F2hc in the initial stages of tumor devel-
opment. This is also in agreement with the observed increase in p21
levels in HeLa-947 cells parallel to a decreased Myc/Max signaling,
which may be responsible for a partial growth arrest. Moreover,
microenvironmental factors as hypoxia have been described as regu-
lators in tumor progression and angiogenesis [47,48]. Interestingly,
the expression of LAT1 (which associates with 4F2hc to enable
heteromeric amino acid transport) is closely correlated with hypoxic
markers and mTOR pathway in patients with non-small cell lung
cancer [49]. Thus, as we have observed a reduced basal activity of
hypoxia/HIF-1α pathway in 4F2hc-silenced cells, this fact could also
contribute to the retarded tumor appearance. In addition, it is worthy
to mention that MMP-2 is one of the gene products induced by HIF
during ECM remodeling [48].
Besides β-integrins, 4F2hc interacts with other proteins on the
plasma membrane. It has been described as a part of a multicom-
ponent complex that includes CD147, EpCAM and ASCT2, regulating
energy metabolism through 5′AMP-activated protein kinase [16].
CD147, which belongs to the immunoglobulin superfamily, acts as
a chaperone and interacts with monocarboxylate transporters
(MCT-1 and MCT-4), β1-integrin and caveolin-1 [50]. Moreover, it
works as a receptor for cyclophilins and its expression is often in-
creased in cancers being correlated with invasiveness, metastasis
and multidrug-resistance phenotype [11,51]. We have found in
HeLa cells co-localization of 4F2hc with both β1-integrin and
CD147, suggesting that these proteins might form a multimolecular
unit in these cells as it has been previously proposed in other cell
types [16,52]. In addition, 4F2hc was localized by sucrose gradients
to the high-density membrane fractions together with galectin-3,
CD147, and the majority of β1-integrins. Thus, 4F2hc association
with β1-integrins does not occur in lipid rafts in HeLa cells, in con-
trast to previous reports on human HT1080 ﬁbrosarcoma cells and
HaCaT keratinocytes, where 4F2hc located in caveolin-rich low den-
sity microdomains [36,53].
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effects on CD147 expression. We have not detected alterations in
HeLa cells after 4F2hc repression neither in CD147 nor β1-integrin
expression. These results are in agreement with data reported for
4F2hc-silenced human promonocytic leukemia THP-1 cells [54]. How-
ever, in HEK293 cells, silencing of either 4F2hc or CD147 diminishes
cell surface expression of each other [16]. Similarly, ovarian cancer
cells, in which 4F2hc was silenced using shRNA presented reduced
CD147 transcription and protein levels [11].
CD147 is a well-known inducer of MMPs and angiogenic factors in
ﬁbroblasts and tumor cells and it has been suggested that it may regu-
late the expression ofMMP-2 andMMP-9 via ERK [20,55]. Inmetastatic
ovarian carcinoma, ERK, p38 and JNK were found to be elevated con-
comitantly with increased MMP-2 production [56]. ERK1/2 activation
may also be a late downstream event of 4F2hc-integrin signaling fol-
lowing activation of PKCδ and PI3K [54]. We have detected a signiﬁcant
decrease in MMP-2 cellular and secreted levels after silencing of 4F2hc,
which is reﬂected in a ~3-fold decrease in extracellular MMP-2 activity,
and decreased ERK and JNK activation, although CD147 and β1-integrin
levelswere notmodiﬁed. Thus,MMP-2 expression and secretion aswell
asMAPK activation inHeLa cells seem to be dependent on the appropri-
ate formation of CD147/4F2hc/β1-integrin heterocomplexes on the cell
surface, failing when CD147 cannot interact with 4F2hc.
The initial steps of tumor cell invasion depend on the ability of can-
cer cells to invade surrounding tissue through both modulation of cell–
cell and cell–matrix interactions and degradation of ECM, processes
in which MMPs play a key role [57,58]. Among them, gelatinasesFig. 9. Proposed role of 4F2hc in galectin-3 and β-catenin signaling in control and silenced He
plasm. (B) Control HeLa cells present CD147/4F2hc/β1-integrin heterocomplexes on the cell su
GSK-3βwhich allownuclear translocation ofβ-catenin and its associationwith TCF/LEF transcri
Akt activity and losing galectin-3 signaling events. This allows GSK-3β-dependent phosphoryl
quent decrease in MMP-2 expression and secretion.(MMP-2 and MMP-9) degrade type-IV collagen, the major component
of basement membrane. This is the ﬁrst barrier for invasion and, conse-
quently, they are often used as prognostic markers and could be consid-
ered therapeutics targets. Clinical trials using MMP inhibitors have
failed up to date. This is probably due to an improper selection of pa-
tients or well to the use of broad-spectrum inhibitors that block not
only MMPs that facilitate cancer progression, but also those with
tumor suppression activities [59]. However, the development of more
speciﬁc MMP inhibitors targeting non-conserved sequences implicated
in substrate selection is still a promising and emerging area of research
for improving therapies [29].
In addition, the endogenous ligand of 4F2hc, galectin-3, has been
described as a substrate for MMPs as it presents a collagen-like region
susceptible to undergo cleavage by gelatinases. This extracellular
cleavage results in a truncated protein (~22 kDa) with a reduced
auto-association and increased afﬁnity to glycoconjugates, whereas
the intact protein oligomerizes and crosslinks glycans in the cell
surface triggering different signaling events [60,61]. Moreover,
galectin-3 cleavage plays an important role in tumor progression
and angiogenesis, and can be used as a surrogate diagnostic marker
for in vivo MMP activity and bad prognosis [62,63]. Interestingly, we
have found that down-regulation of 4F2hc not only impairs MMP-2
expression and activity, but also is reﬂected in a signiﬁcant increase
in extracellular (but not cytoplasmic) galectin-3 levels. This accu-
mulation is probably a consequence of the diminished MMP-2
expression/activity in the extracellular milieu, as it can be reproduced
by using the MMP inhibitor Batimastat in conditioned media fromLa cells. (A) HeLa cells lack E-cadherin expression and β-catenin remains free in the cyto-
rface, which contribute to Akt activation with concomitant phosphorylation/inhibition of
ption factors. (C) 4F2hc-silenced cells cannot form the heterocomplex, presentingminimal
ation of β-catenin, ubiquitination by β-TrCP and proteasomal degradation, with a conse-
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cells could explain, at least partially, the increased lag phase during
tumor implantation in nude mice.
It has been reported that galectin-3 mediates β-catenin signaling
by regulation of GSK-3β phosphorylation and activity via the PI3K/
Akt pathway. Galectin-3 activates Akt promoting its phosphorylation
which, in turn, phosphorylates GSK-3β. This leads to a decreased
GSK-3β activation and the subsequent accumulation/translocation
of β-catenin into the nucleus where it binds to TCF/LEF and activates
the transcription of speciﬁc target genes that promote cell growth
and survival [62,64]. Among them, several genes are involved in the
epithelial–mesenchymal transition (EMT) (as Slug and Snail), in the
regulation of the cell cycle and proliferation (e.g. c-Myc or cyclin
D1) or encode MMPs; all of these genes contribute to enhance inva-
siveness and tumorigenic potential of transformed cells [65]. Howev-
er, the mechanism by which galectin-3 enhances PI3K/Akt activities
has not yet been elucidated.
Does the extracellular galectin-3 accumulation in 4F2hc-silenced
cells have any effect on these cells? When β-catenin pathway was
analyzed, we detected decreased activation of Akt that allowed fur-
ther activation of GSK-3β and cleavage of β-catenin (whose levels
were reduced both in cytosol and nucleus). This apparent contradic-
tion to the reported effects of galectin-3 could be explained by a
dependency on its interaction with 4F2hc in HeLa cells. Thus, in con-
trol cells, galectin-3 would interact with the heterocomplex formed
by 4F2hc, CD147 and β1-integrins, modulating integrin-dependent
signaling and FAK activation, leading to downstream events such as
stimulation of Rac/Ras/Raf/ERK and PI3K/Akt pathways [5]. Active
Akt phosphorylates GSK-3β promoting its inactivation and, therefore,
inhibits β-catenin degradation (Fig. 9B). On the other hand, although
galectin-3 extracellular levels are elevated when 4F2hc is down-
regulated, it is unable to efﬁciently interact with the cell surface
resulting in a minimal FAK activation. This decreases Akt phosphory-
lation and eventually leads to β-catenin proteasomal degradation
mediated by β-TrCP ubiquitination [41]. Thus, the ﬁnal consequences
of 4F2hc silencing are mainly related to a diminished transcriptional
activity of β-catenin/TCF/LEF complexes (Fig. 9C). In fact, repression
of MMPs could be a consequence of this transcriptional repression,
together with the decreased activity of Myc or hypoxia pathways
detected in signaling array.
HeLa cells are a classic representative example of epithelial tumor
cells that have undergone EMT, in which cells acquire a mesenchymal
phenotype increasing the expression of matrix degrading enzymes
and losing some characteristic epithelial markers as E-cadherin [66].
In fact, the absence of E-cadherin in HeLa cells increases concentra-
tion of cytosolic free β-catenin (Fig. 9A–B). Here we have described
that 4F2hc-silencing induces β-catenin degradation, together with
down-regulation of MMP-2 and hypoxia/HIF-1α pathway, and a sig-
niﬁcant loss of motility/invasiveness (as detected in the in vitro
wound healing assays). All of these results point out to a certain de-
gree of EMT reversal in these cells in agreement with their decreased
tumorigenicity. Supporting this hypothesis, it has been described that
inhibition of Wnt signaling through β-catenin shRNA causes a rever-
sal of EMT and metastatic phenotypes induced by HIF1-α in human
prostate cancer [67].
5. Conclusions
In summary, we have described for the ﬁrst time that 4F2hc plays an
important role in the regulation ofMMP-2 expression/secretion andmo-
tility in HeLa cells. 4F2hc silencing alters cell proliferation in vitro and in
vivo by modulation of integrin-dependent signaling pathways such as
FAK, Akt, ERK or JNK, and impairs CD147 functionality with a reduced
MMP-2 expression. Furthermore, repression of 4F2hc leads to a blockage
of galectin-3 signaling events, an increased degradation of β-catenin and
diminished hypoxia signaling that might be responsible for a partialreversal of the malignant phenotype. These results allow a better
knowledge on the molecular mechanism by which 4F2hc promotes
tumorigenicity. In addition, the miRNA-mediated downregulation of
4F2hc expression here presented could be considered as an encouraging
therapeutic approach for anti-cancer therapies based on inhibition of
integrin signaling in epithelial cancers.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.04.017.
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